Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.37 -0.09 (-0.58%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 Next >
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
From Takeda Pharmaceutical Company Limited
Via Business Wire
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
From Takeda Pharmaceutical Company Limited
Via Business Wire
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.